

Torsades De Pointes

[View the current Torsades De Pointes InDepth page on BioPortfolio.com](http://www.bioportfolio.com/indepth/Torsades_De_Pointes.html) ([PDF](#))

(http://www.bioportfolio.com/indepth/Torsades_De_Pointes.html) - Regularly Updated.

Recent Publications on Torsades De Pointes:



- [Sudden death in patients receiving drugs tending to prolong the QT interval.](#)
*AIMS: To examine risks of sudden death in the community associated with...*18th November, 2009
Schools of Health & Population Sciences, University of Birmingham College- Br J Clin Pharmacol. 2009 Nov;68(5):743-51. ([DOI Direct Link](#))
- [Torsades de Pointes induced by a combination of garenoxacin and disopyramide and other cytochrome P450, family 3, subfamily A polypeptide-4-influencing drugs during hypokalemia due to licorice.](#)
*We report an 82-year-old man who developed ventricular tachycardia and...*17th November, 2009
Division of Nephrology and Rheumatology, Department of Internal Medicine,- Clin Exp Nephrol. 2009 Nov 14. ([DOI Direct Link](#))
- [Inter-rater reliability of manual QT measurement and prediction of abnormal QT,HR pairs.](#)
*OBJECTIVES: To assess interobserver agreement when trained healthcare...*17th November, 2009
Department of Clinical Toxicology and Pharmacology, Calvary Mater- Clin Toxicol (Phila). 2009 Nov;47(9):884-8. ([DOI Direct Link](#))
- [Drugs, electrolytes and tako-tsubo cardiomyopathy: triple aetiology of acquired long QT syndrome and torsades de pointes.](#)
*We report an 82-year-old man who developed ventricular tachycardia and...*13th November, 2009
- Ulster Med J. 2009 Sep;78(3):188-9.
- [Roscovitine binds to novel L-channel \(Cav1.2\) sites that separately affect activation and inactivation.](#)
*L-type (CaV1.2) calcium channel antagonists play an important role in the...*6th November, 2009
Penn State College of Medicine, United States.- J Biol Chem. 2009 Nov 2. ([DOI Direct Link](#))
- [The genetic basis of long QT and short QT syndromes: a mutation update.](#)
*Long QT and short QT syndromes (LQTS and SQTs) are cardiac repolarization...*29th October, 2009
Department of Clinical Biochemistry and Immunology, Statens Serum- Hum Mutat. 2009 Nov;30(11):1486-511. ([DOI Direct Link](#))
- [Pharmacokinetics, bioavailability and effects on electrocardiographic parameters of oral fludarabine phosphate.](#)
*The pharmacokinetics, bioavailability and effects on electrocardiographic...*29th October, 2009
Departments of Clinical Pharmacology and Clinical Development, Antisoma- Biopharm Drug Dispos. 2009 Oct 26. ([DOI Direct Link](#))
- [Long QT syndrome and torsades de pointes induced by acute sulpiride poisoning.](#)
*Sulpiride, a selective dopamine D2 antagonist and a substituted benzamide...*28th October, 2009
Institute of Forensic Medicine, College of Medicine, National Taiwan- Am J Emerg Med. 2009 Oct;27(8):1016.e1-3. ([DOI Direct Link](#))

- [New and emerging antiarrhythmic drugs for atrial fibrillation: what may become available to the clinician in the near future.](#)
*Atrial fibrillation (AF) is the most prevalent cardiac arrhythmia and a...*23rd October, 2009
Peter J. Zimetbaum, MD Division of Cardiology, Beth Israel Deaconess- *Curr Treat Options Cardiovasc Med.* 2009 Oct;11(5):373-80.
- [Latent genetic backgrounds and molecular pathogenesis in drug-induced long-QT syndrome.](#)
*BACKGROUND: Drugs with I(Kr)-blocking action cause secondary long-QT...*22nd October, 2009
Department of Cardiovascular and Respiratory Medicine, Shiga University of- *Circ Arrhythm Electrophysiol.* 2009 Oct;2(5):511-23. Epub 2009 Aug 2. ([DOI Direct Link](#))
- [Does the sedative agent, JM-1232\(-\) cause QT prolongation with subsequent torsades de pointes?](#)
*AIMS: JM-1232(-)...*17th October, 2009
Laboratory of Clinical Pharmacy and Clinical Pharmacokinetics, Osaka- *Life Sci.* 2009 Nov 18;85(21-22):737-41. Epub 2009 Oct 12. ([DOI Direct Link](#))
- [The Effect of Oral Methadone on the QTc Interval in Advanced Cancer Patients: A Prospective Pilot Study.](#)
*Abstract Background: Recent reports suggest that high doses of methadone...*15th October, 2009
Department of Palliative Care & Rehabilitation Medicine, University of- *J Palliat Med.* 2009 Oct 13. ([DOI Direct Link](#))
- [Mechanisms of Drug Induced QT Interval Prolongation.](#)
*The long QT syndrome (LQTS) is characterized by a prolonged QT interval,...*10th October, 2009
Pharmacovigilance Unit, Second Chair of Pharmacology, School of Medicine,- *Curr Drug Saf.* 2009 Oct 7.
- [QT Interval Prolongation: Preclinical and Clinical Testing Arrhythmogenesis in Drugs and Regulatory Implications.](#)
*The assessment about the proarrhythmic risk associated with a particular...*10th October, 2009
Department of Cardiology, Instituto FLENI, and Institute of- *Curr Drug Saf.* 2009 Oct 7.
- [Antihistamines: Past Answers and Present Questions.](#)
*Antihistamines are drugs frequently used. Several drugs in this family had...*10th October, 2009
Pharmacovigilance Unit, Second Chair of Pharmacology, School of Medicine,- *Curr Drug Saf.* 2009 Oct 7.

BioNews Results for Torsades De Pointes

- [Life-threatening Torsades de Pointes resulting from 'natural' cancer treatment](#)
Bioscience Technology Online: Nov 19 2009 1:34AM Matching: torsades de pointes
- [Torsades de Pointes induced by a combination of garenoxacin and disopyramide and other cytochrome P450, family 3, subfamily A polypeptide-4-influencing drugs during hypokalemia due to licorice](#)
MDLinx: Nov 18 2009 1:35PM Matching: torsades de pointes

Torsades De Pointes Patents:



- 7429646- [Antibodies to human tumor necrosis factor receptor-like 2](#)
- 7482334- [Therapeutic treatment methods](#)
- 7498027- [Methods of treatment using human tumor necrosis factor receptor TR17 antibodies](#)
- 7498449- [Antiarrhythmic precursor compounds, methods of synthesis and methods of use](#)
- 7501123- [Human G-protein chemokine receptor \(CCR5\) HDGMR10](#)
- 7501436- [5-HT3 receptor antagonists and methods of use](#)
- 7504105- [Treatment using antibodies to cytokine receptor common gamma chain like](#)
- 7504481- [TRP channel family member, LTRPC3 polypeptides](#)
- 7504517- [Kv1.5 potassium channel inhibitors](#)
- 7507413- [Albumin fusion proteins](#)
- 7507414- [Albumin fusion proteins](#)
- 7482013- [Albumin fusion proteins](#)
- 7476384- [Death domain containing receptor 4 antibody and methods](#)
- 7470678- [Diphenylazetidinone derivatives for treating disorders of the lipid metabolism](#)
- 7432308- [Therapeutic compositions for the treatment of a respiratory tract disease](#)
- 7435808- [Polynucleotides encoding novel adiponectin receptor variant, AdipoR2v2](#)
- 7435861- [Methods for synthesis of carotenoids, including analogs, derivatives, and synthetic and biological intermediates](#)
- 7446176- [12 human secreted proteins](#)
- 7452538- [Death domain containing receptor 4 antibodies and methods](#)
- 7456256- [BGS 4](#)
- 7459531- [50 Human secreted proteins](#)
- 7459532- [Variants of the TRP channel family member, LTRPC3G](#)
- 7465707- [Methods of treatment with TR10 polypeptides](#)
- 7465848- [Zebrafish assay](#)
- 7507545- [Ion channel modulating activity method](#)
- 7510874- [Stable cell lines expressing HERG1a and HERG1b](#)
- 7557138- [5-phenoxyalkoxypsoralens and methods for selective inhibition of the voltage gated Kv1.3 potassium channel](#)
- 7560561- [Process for production of piperidine derivatives](#)
- 7569384- [Albumin fusion proteins](#)
- 7572618- [Polynucleotides encoding novel PCSK9 variants](#)
- 7592010- [Albumin fusion proteins](#)
- 7595038- [Methods of treatment using antibodies to follistatin-3](#)
- 7595300- [7-quinolyl ketolide antibacterial agents](#)
- 7597886- [Tumor necrosis factor-gamma](#)
- 7598348- [Adiponectin receptor variant, AdipoR2v2](#)
- 7608458- [Identifying patients at risk for life threatening arrhythmias](#)
- 7550569- [Antibodies that specifically bind to GMAD](#)
- 7547687- [Therapeutic treatment methods](#)
- 7541476- [Radiolabeled astemizole and method of making](#)
- 7511017- [Methods of treatment with TNFR5](#)
- 7514582- [2'-substituted 1,1'-biphenyl-2-carboxamides, processes for their preparation, their use as medicaments, and pharmaceutical preparations comprising them](#)
- 7521424- [Albumin fusion proteins](#)
- 7521584- [Carotenoid analogs or derivatives for the inhibition and amelioration of disease](#)
- 7524879- [Ion channel modulating compounds and uses thereof](#)
- 7531310- [Methods of diagnosing Crohn's disease by measuring expression level of RNA encoding human G-protein coupled receptor, HGPRBMY11](#)
- 7534428- [Antibodies to tumor necrosis factor receptors 6.alpha. and 6.beta.](#)
- 7534790- [Ion channel modulating compounds and uses thereof](#)
- 7534903- [Use of amidomethyl-substituted 2-\(4-sulfonylamino\)-3-hydroxy-3,4-dihydro-2H-chromen-6-yl-compounds in the treatment of cardiac](#)

[arrhythmia and other disease states](#)

- 7537928- [Mutations in ion channel proteins associated with sudden cardiac death](#)
- 7611852- [Functional cardiomyocytes from human embryonic stem cells](#)

Resources from the [NCBI](#) used in this document, [NCBI's standard disclaimer applies](#).

Nothing in this document should be used in place of personal medical advice from your own qualified medical practitioner. See BioPortfolio.com [User Agreement](#)

Send comments and feedback to:

Peter Barfoot Managing Director, BioPortfolio Ltd.

UK Tel: (+44) 1300 321501

USA Voicemail and Fax: (+1) 415 680 2472

[Peter Barfoot peter.barfoot@bioportfolio.com](mailto:peter.barfoot@bioportfolio.com)

All rights reserved. All other trademarks recognized.

BioPortfolio Limited is registered in England & Wales at Stafford House, 10 Prince of Wales Road, Dorchester, Dorset, DT1 1PW, UK. No.3312883 VAT No. GB 744 6483 10

Copyright 1997-2009 - BioPortfolio Limited.

